Skin is an easily accessible organ, and therapeutic gene transfer to skin remains an attractive alternative for the treatment of skin diseases. Although we have previously documented potent lentiviral gene delivery to human skin, vectors based on adeno-associated virus (AAV) rank among the most promising gene delivery tools for in vivo purposes. Thus, we compared the potential usefulness of various serotypes of recombinant AAV vectors and lentiviral vectors for gene transfer to human skin in a xenotransplanted mouse model. Vector constructs encoding firefly luciferase were packaged in AAV capsids of serotype 1, 2, 5, 6, 8, and 9 and separately administered by intradermal injection in human skin transplants. For all serotypes, live bioimaging demonstrated low levels of transgene expression in the human skin graft, and firefly luciferase expression was observed primarily in neighboring tissue outside of the graft. In contrast, gene delivery by intradermally injected lentiviral vectors was efficient and led to extensive and persistent firefly luciferase expression within the human skin graft only. The study demonstrates the limited capacity of single-stranded AAV vectors of six commonly used serotypes for gene delivery to human skin in vivo.
Get full access to this article
View all access options for this article.
References
1.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
2.
MaguireAM, HighKA, AuricchioA, et al.Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet, 2009; 374:1597–1605.
3.
HauswirthWW, AlemanTS, KaushalS, et al.Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 2008; 19:979–990.
4.
RabinowitzJE, RollingF, LiC, et al.Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol, 2002; 76:791–801.
5.
KawaseY, LyHQ, PrunierF, et al.Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol, 2008; 51:1112–1119.
6.
WhiteJD, ThesierDM, SwainJB, et al.Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther, 2011; 18:546–552.
7.
PacakCA, MahCS, ThattaliyathBD, et al.Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res, 2006; 99:e3–e9.
8.
FlotteTR, TrapnellBC, HumphriesM, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther, 2011; 22:1239–1247.
9.
WangZ, StorbR, HalbertCL, et al.Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther, 2012; 20:1501–1507.
10.
Rodino-KlapacLR, MontgomeryCL, BremerWG, et al.Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther, 2010; 18:109–117.
11.
HutsonTH, VerhaagenJ, Yanez-MunozRJ, et al.Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector. Gene Ther, 2012; 19:49–60.
12.
BurgerC, GorbatyukOS, VelardoMJ, et al.Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther, 2004; 10:302–317.
13.
SamaranchL, SalegioEA, San SebastianW, et al.Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther, 2012; 23:382–389.
14.
FlotteTR, FischerAC, GoetzmannJ, et al.Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther, 2010; 18:594–600.
15.
HalbertCL, MadtesDK, VaughanAE, et al.Expression of human α1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther, 2010; 18:1165–1172.
16.
Liqun WangR, McLaughlinT, CossetteT, et al.Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of α-1-antitrypsin using invasive and noninvasive delivery. Mol Ther, 2009; 17:81–87.
17.
PfeiferC, AnejaMK, HasenpuschG, et al.Adeno-associated virus serotype 9-mediated pulmonary transgene expression: effect of mouse strain, animal gender and lung inflammation. Gene Ther, 2011; 18:1034–1042.
18.
PangJJ, DengWT, DaiX, et al.AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PloS One, 2012; 7:e35250.
19.
VandenbergheLH, BellP, MaguireAM, et al.Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med, 2011; 3:88ra54.
20.
BakRO, StenderupK, RosadaC, et al.Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol, 2011; 11:5.
21.
SiprashviliZ, and KhavariPA. Lentivectors for regulated and reversible cutaneous gene delivery. Mol Ther, 2004; 9:93–100.
22.
JakobsenM, StenderupK, RosadaC, et al.Amelioration of psoriasis by anti-TNF-α RNAi in the xenograft transplantation model. Mol Ther, 2009; 17:1743–1753.
23.
JazwaA, KucharzewskaP, LejaJ, et al.Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice. Genet Vaccines Ther, 2010; 8:6.
24.
KeswaniSG, BalajiS, LeL, et al.Pseudotyped adeno-associated viral vector tropism and transduction efficiencies in murine wound healing. Wound Repair Regen, 2012; 20:592–600.
25.
Braun-FalcoM, EisenriedA, BuningH, et al.Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase. Arch Dermatol Res, 2005; 296:528–535.
26.
EllisBL, HirschML, BarkerJC, et al.A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1–9) and one engineered adeno-associated virus serotype. Virol J, 2013; 10:74.
27.
PetekLM, FleckmanP, and MillerDG. Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex. Mol Ther, 2010; 18:1624–1632.
28.
Gagnoux-PalaciosL, HervouetC, SpiritoF, et al.Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J Gene Med, 2005; 7:1178–1186.
29.
PrimoMN, BakRO, SchiblerB, et al.Regulation of pro-inflammatory cytokines TNFα and IL24 by microRNA-203 in primary keratinocytes. Cytokine, 2012; 60:741–748.
30.
StenderupK, RosadaC, WorsaaeA, et al.Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol, 2009; 160:284–296.
31.
ChenH. Comparative observation of the recombinant adeno-associated virus 2 using transmission electron microscopy and atomic force microscopy. Microsc Microanal, 2007; 13:384–389.
32.
BriggsJA, WilkT, WelkerR, et al.Structural organization of authentic, mature HIV-1 virions and cores. EMBO J, 2003; 22:1707–1715.
33.
WuZ, MillerE, Agbandje-McKennaM, et al.α2,3 and α2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol, 2006; 80:9093–9103.
34.
WaltersRW, YiSM, KeshavjeeS, et al.Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem, 2001; 276:20610–20616.
35.
NgR, GovindasamyL, GurdaBL, et al.Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol, 2010; 84:12945–12957.
36.
Di PasqualeG, DavidsonBL, SteinCS, et al.Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med, 2003; 9:1306–1312.
37.
WellerML, AmornphimolthamP, SchmidtM, et al.Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med, 2010; 16:662–664.
38.
HolikovaZ, Hrdlickova-CelaE, PlzakJ, et al.Defining the glycophenotype of squamous epithelia using plant and mammalian lectins: differentiation-dependent expression of α2,6- and α2,3-linked N-acetylneuraminic acid in squamous epithelia and carcinomas, and its differential effect on binding of the endogenous lectins galectins-1 and −3. APMIS, 2002; 110:845–856.
39.
TomasD, VucicM, SitumM, et al.The expression of syndecan-1 in psoriatic epidermis. Arch Dermatol Res, 2008; 300:393–395.
40.
NanneyLB, McKannaJA, StoscheckCM, et al.Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol, 1984; 82:165–169.
41.
RollmanO, JensenUB, OstmanA, et al.Platelet derived growth factor (PDGF) responsive epidermis formed from human keratinocytes transduced with the PDGF β receptor gene. J Invest Dermatol, 2003; 120:742–749.
42.
SummerfordC, and SamulskiRJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 1998; 72:1438–1445.
43.
QingK, MahC, HansenJ, et al.Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med, 1999; 5:71–77.
44.
SummerfordC, BartlettJS, and SamulskiRJ. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med, 1999; 5:78–82.
45.
AsokanA, HamraJB, GovindasamyL, et al.Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J Virol, 2006; 80:8961–8969.
46.
TakenakaH, YasunoH, and KishimotoS. Immunolocalization of fibroblast growth factor receptors in normal and wounded human skin. Arch Dermatol Res, 2002; 294:331–338.
47.
AdamsJC, and WattFM. Expression of β1, β3, β4, and β5 integrins by human epidermal keratinocytes and non-differentiating keratinocytes. J Cell Biol, 1991; 115:829–841.
48.
SallachJ, Di PasqualeG, LarcherF, et al.Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol Ther, 2014; 22:929–939.
49.
ShenS, BryantKD, BrownSM, et al.Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem, 2011; 286:13532–13540.
50.
AkacheB, GrimmD, PandeyK, et al.The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol, 2006; 80:9831–9836.
51.
GeorgiouS, PasmatziE, MonastirliA, et al.Age-related alterations in the carbohydrate residue composition of the cell surface in the unexposed normal human epidermis. Gerontology, 2005; 51:155–160.
52.
CavalieriS, RotoliM, FelicianiC, et al.Expression of the high-affinity laminin receptor (67 kDa) in normal human skin and appendages. Int J Immunopathol Pharmacol, 2005; 18:223–231.
53.
FisherKJ, GaoGP, WeitzmanMD, et al.Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol, 1996; 70:520–532.
54.
McCartyDM, MonahanPE, and SamulskiRJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther, 2001; 8:1248–1254.
55.
MeloSP, LisowskiL, BashkirovaE, et al.Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant. Mol Ther, 2014; 22:725–733.
56.
LisowskiL, DaneAP, ChuK, et al.Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014; 506:382–386.
57.
ZhongL, LiB, JayandharanG, et al.Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology, 2008; 381:194–202.
58.
QiaoC, ZhangW, YuanZ, et al.Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther, 2010; 21:1343–1348.
59.
Petrs-SilvaH, DinculescuA, LiQ, et al.High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther, 2009; 17:463–471.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
